Difference between revisions of "Cytarabine and daunorubicin liposomal (Vyxeos)"
Jump to navigation
Jump to search
m |
m |
||
Line 13: | Line 13: | ||
[[Category:Anthracyclines]] | [[Category:Anthracyclines]] | ||
− | [[Category: | + | [[Category:Antimetabolites]] |
+ | [[Category:Deoxycytidine analogues]] | ||
+ | [[Category:Topoisomerase inhibitors]] | ||
[[Category:Acute myeloid leukemia medications]] | [[Category:Acute myeloid leukemia medications]] | ||
[[Category:Investigational]] | [[Category:Investigational]] |
Revision as of 20:45, 11 December 2014
Mechanism of action
This drug is a liposomal formulation of Cytarabine (Cytosar) and Daunorubicin (Cerubidine) in a 5:1 molar ratio.
Preliminary data
Acute myeloid leukemia
- Lancet JE, Cortes JE, Hogge DE, Tallman MS, Kovacsovics TJ, Damon LE, Komrokji R, Solomon SR, Kolitz JE, Cooper M, Yeager AM, Louie AC, Feldman EJ. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood. 2014 May 22;123(21):3239-46. Epub 2014 Mar 31. link to original article PubMed
- Cortes JE, Goldberg SL, Feldman EJ, Rizzeri DA, Hogge DE, Larson M, Pigneux A, Recher C, Schiller G, Warzocha K, Kantarjian H, Louie AC, Kolitz JE. Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. Cancer. 2014 Sep 15. [Epub ahead of print] link to original article PubMed